KPL.BO Kwality Pharmaceuticals BSE +24.72% 13 Feb 2026 after hours: top gainer

KPL.BO stock surged 24.72% in after-hours trade on 13 Feb 2026, closing at INR 1,431.20 on the BSE. The move came with heavy volume of 182,279 shares versus an average of 16,373, signalling strong buying interest. Key fundamentals show EPS 47.28 and PE 28.81, while technicals (RSI 69.16) point to robust momentum. In this after-hours top-gainers note we break down what moved Kwality Pharmaceuticals Limited (KPL.BO), the valuation trade-offs, and how short-term momentum compares with longer-term Meyka forecasts and sector context.

KPL.BO stock performance snapshot

Kwality Pharmaceuticals Limited (KPL.BO) strengthened to INR 1,431.20, up 24.72% from the previous close of INR 1,147.50 on the BSE. The intraday range logged a day low INR 1,321.10 and day high INR 1,456.00. Volume spiked to 182,279 versus average volume 16,373, giving a relative volume of 15.38 and confirming a high-conviction rally in after-hours trade.

Drivers behind the after-hours jump

The price jump appears driven by stronger-than-expected earnings metrics and renewed sector interest in healthcare names. Reported EPS 47.28 and a trailing PE 28.81 gave investors a clear earnings anchor. The stock also outperformed the Healthcare sector average PE of 39.20, making KPL.BO stock relatively cheaper on earnings terms and attractive to growth-leaning buyers.

Fundamentals and valuation analysis

On fundamentals Kwality shows revenue per share INR 407.29, book value per share INR 277.99, and cash per share INR 32.82. Key ratios: P/S 3.34, P/B 4.87, Debt/Equity 0.38, and ROE 18.58%. While ROE and margins (net margin 11.61%) are healthy, the P/B 4.87 sits above the healthcare sector average P/B 2.54, indicating premium paid for profitability and growth expectations.

Technicals and trading signals

Technical indicators show momentum but caution for new buyers. RSI is 69.16 and MACD histogram is positive (6.44), signalling bullish momentum. Price sits well above the 50-day average (INR 1,059.66) and 200-day average (INR 992.48). Volatility measures include ATR INR 58.73 and MFI 76.47, suggesting heavy money flow and a potential near-term overbought state.

Meyka AI rates KPL.BO with a score out of 100

Meyka AI rates KPL.BO with a score out of 100: 71.07 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights strong profitability (ROE 18.58%) and manageable leverage (debt/equity 0.38), while noting valuation premiums relative to peers. See the full stock page on Meyka for live tools and signals: KPL.BO on Meyka.

Risks and opportunities for KPL.BO stock

Key risks: a long receivables cycle (DSO 141.20 days) and limited free cash flow disclosures (operating cash flow per share reported as 0.00 in the dataset). Opportunities include strong margin profile (gross margin 45.47%) and sector defensiveness as Healthcare outperforms in volatile markets. Investors should weigh higher valuation multiples against sustained margin and ROCE (30.93%) expansion potential. For company filings and corporate updates see the company site and BSE pages source source.

Final Thoughts

KPL.BO stock’s after-hours gain of 24.72% to INR 1,431.20 on 13 Feb 2026 reflects a sharp momentum swing on heavy volume and earnings-driven positioning. Short-term technicals favour bulls, yet indicators show near-overbought conditions (RSI 69.16, MFI 76.47). On valuation, the company posts solid returns (ROE 18.58%) and modest leverage (debt/equity 0.38), but trades at a premium P/B 4.87 versus sector averages. Meyka AI’s forecast model projects a yearly target of INR 1,112.81 (implied -22.26% vs current INR 1,431.20) and a five-year target of INR 1,637.68 (implied +14.44%). These model-based projections highlight a near-term re-rating risk and a medium-term upside case. Our analyst view: a tactical trader may ride momentum with strict stop-loss placement, while long-term investors should await confirmation of cash flow strength or a nearer-term pullback. Meyka AI, as an AI-powered market analysis platform, provides the score and forecasts used here; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.